Endoscopic ultrasound (EUS) and the management of pancreatic cancer

Muhammad Nadeem Yousaf,1,2,3,4 Fizah S Chaudhary,2,3,4 Amrat Ehsan,2,3,4 Alejandro L Suarez,1 Thiruvengadham Muniraj,1 Priya Jamidar,1 Harry R Aslanian,1 James J Farrell1

ABSTRACT
Pancreatic cancer is one of the leading causes of cancer-related mortality in western countries. Early diagnosis of pancreatic cancers plays a key role in the management by identification of patients who are surgical candidates. The advancement in the radiological imaging and interventional endoscopy (including endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography and endoscopic enteral stenting techniques) has a significant impact in the diagnostic evaluation, staging and treatment of pancreatic cancer. The multidisciplinary involvement of radiology, gastroenterology, medical oncology and surgical oncology is central to the management of patients with pancreatic cancers. This review aims to highlight the diagnostic and therapeutic role of EUS in the management of patients with pancreatic malignancy, especially pancreatic ductal adenocarcinoma.

INTRODUCTION
Pancreatic cancer is the fourth leading causes of cancer-related death in the USA with an estimated of 55,600 (30,400 men and 25,200 women) new cases, and 47,050 (24,640 men and 22,410 women) deaths in 2020.1 The highest incidence rate is reported in North America and Europe while lowest in Africa and South Central.2 The common risk factors for pancreatic cancer are smoking, positive family history, genetics, alcohol consumption, obesity, diabetes, diet and physical inactivity.3-5 Overall 5-year survival rate is 8% (ranging from 2% to 9%).6-9 The poor outcome of the disease is due to metastatic or local advancement of disease at time of diagnosis in the majority of patients. The introduction of newer medical therapies (including neoadjuvant chemotherapy approaches) and improvement of surgical techniques for resection of pancreatic cancer has had modest impact on the outcome of disease in last decade. Because of the rising disease burden, there is an increasing emphasis on early identification of pancreatic cancers and premalignant pancreatic lesions in high-risk individuals. Advancement in technology to improve both non-invasive imaging (CT scan, MRI, nuclear imaging) and minimally invasive imaging (endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP)) plays an important role in early detection of pancreatic cancers. Specifically, EUS has a central role in diagnosis, staging, palliative therapy and increasingly the therapy of pancreatic cancers.

ENDOSCOPIC ULTRASOUND
EUS is an endoscopic imaging modality which provides a detailed and high-resolution spatial imaging of the pancreas compared with CT or MRI through the addition of an ultrasound transducer on the tip of the flexible endoscope.10 Linear EUS performs imaging in the same plane as shaft of the endoscope, whereas with radial EUS circumferential viewing can be obtained in the plane perpendicular to the shaft of the endoscope. EUS provides the added advantage of high resolution imaging for the identification and evaluation of small pancreatic masses and cysts by taking magnified imaging due to close proximity of EUS transducer to the pancreas by positioning the transducer in the gastro-oesophageal junction (GOJ), bulb and second portion of the duodenum, and by eliminating the effect of intestinal gas and fat.

EUS-GUIDED DIAGNOSTIC INTERVENTIONS
EUS evaluation of solid pancreatic mass lesions
Because of the rising incidence of pancreatic cancer and limited treatment, there is increased emphasis on early detection of pancreatic cancer. Pancreatic intraepithelial neoplasm (PanIN) is a preinvasive form of pancreatic cancer, has potential for malignant transformation to pancreatic adenocarcinoma. It has been suggested that early PanIN 1 lesions can progress to adenocarcinoma in 1.3% in women and 1.5% in men.
over a lifetime period, and that more advanced PanIN 3 lesions can progress to adenocarcinoma over an estimated period of 12.3 years in women and 11.3 years in men. However, due to lack of optimum screening tests including the ability to visualize these PanIN lesions, early detection of pancreatic lesions is challenging. Pancreatic cancer screening of the general population is not recommended because of low disease prevalence. The screening of high-risk populations including those with familial pancreatic cancer and those with known germline genetic mutations for the development of pancreatic cancers (e.g., BRCA2, BRCA1, p16) are the potential targets. Non-invasive imaging (such as MRI and CT scan) and minimally invasive imaging with EUS are the main screening tools for these high-risk populations. Early data suggest a survival benefit to diagnosing early pancreatic cancer within these high surveillance programs.

**Table 1** Prospective/retrospective studies on diagnostic performance of EUS versus CT for detection of pancreatic malignancy

<table>
<thead>
<tr>
<th>Study</th>
<th>Year of study</th>
<th>Total no of patients</th>
<th>Sensitivity, EUS versus CT (%)</th>
<th>Specificity, EUS versus CT (%)</th>
<th>Accuracy, EUS versus CT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Du et al</td>
<td>2017</td>
<td>68</td>
<td>98 vs 73*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kamata et al</td>
<td>2014</td>
<td>35</td>
<td>100 vs 56*</td>
<td>100 vs 100</td>
<td>NA</td>
</tr>
<tr>
<td>Kitano et al</td>
<td>2012</td>
<td>277</td>
<td>91 vs 71*</td>
<td>94 vs 92</td>
<td>NA</td>
</tr>
<tr>
<td>Sakamoto et al</td>
<td>2008</td>
<td>156</td>
<td>94 vs 50*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Jemma et al</td>
<td>2008</td>
<td>42</td>
<td>100 vs 88*</td>
<td>89 vs 83</td>
<td>NA</td>
</tr>
<tr>
<td>Kitano et al</td>
<td>2004</td>
<td>65</td>
<td>95 vs 68*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Agarwal et al</td>
<td>2004</td>
<td>81</td>
<td>100 vs 75*</td>
<td>NA</td>
<td>94 vs 74*</td>
</tr>
<tr>
<td>DeWitt et al</td>
<td>2004</td>
<td>120</td>
<td>98 vs 86*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Rivadeneira et al</td>
<td>2003</td>
<td>48</td>
<td>100 vs 68*</td>
<td>75 vs 50*</td>
<td>98 vs 67*</td>
</tr>
<tr>
<td>Mertz et al</td>
<td>2000</td>
<td>35</td>
<td>93 vs 53*</td>
<td>NA</td>
<td>86 vs 49*</td>
</tr>
<tr>
<td>Gress et al</td>
<td>1999</td>
<td>151</td>
<td>100 vs 74</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Harrison et al</td>
<td>1999</td>
<td>19</td>
<td>100 vs 50*</td>
<td>NA</td>
<td>98 vs 63*</td>
</tr>
<tr>
<td>Midwinter et al</td>
<td>1999</td>
<td>48</td>
<td>97 vs 76</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Legmann et al</td>
<td>1998</td>
<td>30</td>
<td>100 vs 92</td>
<td>NA</td>
<td>93 vs 93</td>
</tr>
<tr>
<td>Sugiyama et al</td>
<td>1997</td>
<td>54</td>
<td>96 vs 89*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Howard et al</td>
<td>1997</td>
<td>21</td>
<td>75 vs 63†</td>
<td>77 vs 100†</td>
<td>76 vs 86†</td>
</tr>
<tr>
<td>Meizer et al</td>
<td>1996</td>
<td>12</td>
<td>100 vs 83</td>
<td>NA</td>
<td>100 vs 76</td>
</tr>
<tr>
<td>Nakazumi et al</td>
<td>1995</td>
<td>232</td>
<td>94 vs 65*</td>
<td>97 vs 94</td>
<td>96 vs 88*</td>
</tr>
<tr>
<td>Marty et al</td>
<td>1995</td>
<td>37</td>
<td>92 vs 63</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Müller et al</td>
<td>1994</td>
<td>49</td>
<td>94 vs 69†</td>
<td>100 vs 64</td>
<td>96 vs 67</td>
</tr>
<tr>
<td>Palazzo et al</td>
<td>1993</td>
<td>64</td>
<td>96 vs 69†</td>
<td>73 vs 53</td>
<td>91 vs 66*</td>
</tr>
<tr>
<td>Yasuda et al</td>
<td>1993</td>
<td>29</td>
<td>100 vs 72†</td>
<td>NA</td>
<td>Na</td>
</tr>
<tr>
<td>Rösch et al</td>
<td>1991</td>
<td>102</td>
<td>99 vs 77</td>
<td>100 vs 53</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Statistically significant data.
† Statistics are not available.
EUS, endoscopic ultrasound; NA, not applicable.
Patients with chronic pancreatitis are at increased risk of developing pancreatic cancer. EUS imaging finding supporting a diagnosis of pancreatic cancer in the setting of chronic pancreatitis are mass size above 2 cm, irregular dilation of the main pancreatic duct and branch duct, vascularity of mass, absence of cysts within mass and presence of lymphadenopathy and vascular invasion.42–43

To discriminate pancreatic cancers from inflammatory pancreatic masses, conventional EUS evaluation alone is often not enough despite high sensitivity and specificity over cross-sectional imaging. The introduction of contrast-enhanced (CE) EUS and EUS elastography may improve the evaluation of pancreatic cancers even in the presence of concomitant autoimmune pancreatitis (AIP) or chronic pancreatitis.44 CE-EUS is a technique which combines high-resolution endoscopy ultrasound waves with intravenous contrast. CE-EUS generates an acoustic signal when ultrasound waves interact with oscillating microbubbles in the intravenous contrast. These acoustic signals help in the assessment of vascularity of pancreatic masses in addition to providing information about echogenicity of lesions. CE-EUS features such as isoenhancement or hypoenhancement, arterial irregularity and absent venous vasculature within a mass favours pancreatic ductal adenocarcinoma (PDAC) while hyperenhanced lesions with the preserved architecture of both arterial and venous microvasculature indicate chronic pancreatitis.45–47 CE-EUS can reliably differentiate pancreatitis from pancreatic cancer with sensitivity, specificity, positive predictive value and negative predictive value of 91%, 93%, 100% and 88% respectively.48 49

It also helps in differentiating pancreatic cystic lesions such as serous cyst adenoma (enhancement of intracystic septation), mucinous cystic neoplasm (MCN) (irregular enhancement of intrasegmental septum and nodule), malignancy intraductal papillary mucinous neoplasms (IPMN) (invasive and papillary mural nodule) and benign IPMN (polypoidal non-invasive papillary nodule).45 47 A meta-analysis on 19 studies has shown pooled sensitivity 91%, specificity 86% for the diagnosis of focal pancreatic masses or PDAC.50

Elastography is a newer non-invasive technique to evaluate stiffness (elasticity) of soft tissue. EUS transducer sends a shear wave through the pancreas and generates an elastogram by calculating velocity faced by shear wave while passing through soft tissue. EUS elastography works as an adjunct to EUS-FNA which may help in the differentiation of malignant from non-malignant masses. The diagnostic yield of EUS elastography is variable, with three meta-analyses showing a 95%–97% pooled sensitivity and 67%–76% specificity.51–53

An algorithm for the evaluation and management of patients with suspected pancreatic adenocarcinoma based on current guidelines is shown in figure 1.15 EUS-FNA should be performed whenever possible for resectable pancreatic cancers to rule out alternative diagnosis.

---

**EUS evaluation of pancreatic cystic lesions**

With the advancement of cross-sectional imaging, the detection rate of incidental pancreatic cyst has increased. The most common incidental pancreatic cystic lesions include mucinous cysts (eg, MCN and IPMNs) pseudocysts and serous cystadenomas.54 Mucinous cystic lesions (which are considered premalignant and occasionally malignant) need to be differentiated from non-mucinous lesions, as they often carry different prognoses and management. EUS and cross-sectional imaging both MRI/CT scans are generally considered to be complimentary for the evaluation of pancreatic cysts. Although MRI is considered superior in the evaluation of pancreatic cystic lesions, a distinct advantage of EUS (especially with improved image resolution) is the ability to sample pancreatic cyst fluid for both cytology and tumor markers including carcinoembryonic antigen (CEA) and DNA mutational analysis.55–59 Under current guidelines, EUS is increasingly reserved for pancreatic cysts with high-risk stigmata or worrisome features where it may impact on
diagnostic workup as well as stratifying patients for either surveillance or surgical resection.16 60

Staging of pancreatic cancers
EUS is a useful modality for the staging of pancreatic cancers in patients with suspected malignancy and assisting in determining surgically resectable lesions. Due to their widespread availability and non-invasive nature, imaging with CT or MRI remains the first-line imaging of choice to perform staging of pancreatic malignancy. For example, advanced cross-sectional imaging from a multidetector CT allows the acquisition of pancreatic arterial phase, pancreatic parenchymal phase and portal venous phase imaging. Pancreatic parenchymal phase and portal venous phase are very useful tools in the identification and precise preoperative vascular staging of pancreatic cancers.61 However, EUS is still an effective tool for evaluation of vascular invasion of tumor, for example, portal vein, superior mesenteric artery (SMA) and superior mesenteric vein notably in patients with small size tumor and in those who cannot undergo CE CT or MRI due to other medical reasons.62 63 EUS also provides additional objective data on perivascular cuffing, assessment of liver masses and local lymph nodes for the staging of pancreatic cancers, especially in individuals who have undergone prior chemotherapy treatment.41 64

EUS-guided FNA
Indications
While CT and MRI imaging may identify a pancreatic mass and strongly suggest an underlying malignancy, pathological diagnosis is necessary to determine the benign or malignant nature of the mass. In the era prior to EUS, the tissue diagnosis of pancreatic masses used to be established by acquisition of tissue specimen by abdominal ultrasound, or CT-guided percutaneous biopsy, or ERCP-guided bile duct brush cytology, or on surgical exploration. The sensitivity of ERCP brush cytology is approximately 30% in the diagnosis of pancreatic malignancy.65 The utility of this approach is limited due to high rate of post ERCP pancreatitis and technical difficulty in obtaining cytology sample especially in case of benign stricture of the pancreatic duct.65 Currently, EUS-FNA biopsy is preferred over these other methods to obtain tissue and for establishing a diagnosis of pancreatic cancer. In case of pancreatic cystic lesions, EUS-FNA helps to distinguish pancreatic cysts with malignant potential (eg, MCN and IPMN) from other cystic lesions without malignant potential (eg, serous cystadenoma). Cyst fluid analysis for cytology, mucin containing goblet cells, tumor markers (CEA), DNA genetic mutation analysis (K-ras), and amylase may help to establish the diagnosis of pancreatic cystic lesions. Recent developments allow for the acquisition of cyst wall tissue by using a through-the-needle biopsy with moray forceps, in addition to the use of through-the-needle confocal microscope probes.

Technical feasibility considerations
EUS-FNA is the technique to obtain tissue for cytological evaluation which can be performed with a linear echoendoscope to target the pancreatic lesion under direct visualization. Tissue acquisition from uncinate, head and neck lesions can be performed by positioning endoscope in the duodenal bulb or second portion of duodenum while tissue from neck, body and tail lesions can be acquired by positioning endoscope in GOJ or proximal stomach. EUS-guided FNA needle targets the pancreatic lesion under direct visualization. Obtaining tissue sample from different areas of the pancreatic lesion is recommended by inserting the needle in a fanning fashion to maximise the yield of biopsy.66 67 Inserting FNA needle to target lesion closer to EUS probe is recommended for technical feasibility as the trajectory of needle may not be modified for distant lesions.68 69 Although there is a risk of needle tract seeding with EUS-FNA, this is often not a concern when the subsequent surgical management includes resection of the pancreatic head.70

Safety
EUS-FNA confers several advantages in the evaluation of pancreatic masses including the ability to target small lesions due to high-resolution imaging in close proximity to the pancreas, less risk to puncturing the intervening organs, avoidance of needle tract tumor seeding and overall cost-effectiveness particularly by avoiding unnecessary additional procedures. The rate of EUS-FNA-associated complications such as pancreatitis, infection, intestinal perforation, biliary peritonitis and malignant seeding is low as compared with other modalities.66 The overall complication rate of EUS-FNA is 2.5% which ensures diagnostic safety of this approach. The risk of pancreatitis ranges from 0.3% to 0.9% with EUS-FNA which is significantly lower than ERCP-guided brush cytology 0%–21.5% and percutaneous biopsies 4%.65 71 The risk of malignant peritoneal seeding is very low with EUS-FNA 2.2% as compared with percutaneous biopsy 16.3%.72

Accuracy
The diagnostic accuracy of EUS-FNA is high for establishing a diagnosis of pancreatic malignancy. EUS-FNA yields an accuracy of 85%–92%, sensitivity of 80%–95% and specificity of 92%–100% in diagnosing pancreatic malignancy.73 74 Several confounding factors such as tumor consistency, needle diameter, number of passes and availability of on-site cytopathologist can affect the diagnostic yield of EUS-FNA. Although the size of EUS-FNA needles varies from 19 to 25 gauge (G), however, most endosonographers use either 25 G or 22 G needles with the dedicated acquisition of tissue for making diagnosis of malignant lesions. A meta-analysis showed a higher yield for 25 G needles for diagnosis of pancreatic cancers with pooled sensitivity of 93% and specificity of 97% as compared with 22 G needle with 85% sensitivity and 99% specificity.75 While there is conflicting information about
the yield of needle size, the added advantage of smaller
gauge needles exhibit less risk of bleeding and easy pene-
tration through desmoplastic tissues. The utilization of
rapid on-site evaluation (ROSE) of cytology specimens
has significantly reduced the need for multiple needle
passes for making a diagnosis whereby the presence of an
on-site cytopathologist advises about specimen adequacy and real-time diagnosis during the procedure.
Multiple studies have shown an increase in the diagnostic yield of this approach by 10%–30% with an accuracy of
93.3%–96.8%, sensitivity of 88.6%–96.2% and specificity of 99%–100%.82–84

**Endoscopic ultrasound fine needle biopsy**

**Indications**

Differentiating pancreatic malignancy from AIP, chronic
pancreatitis and pancreatic lymphoma or tuberculosis
may be challenging because EUS-FNA may not provide
sufficient tissue for molecular and histological evalua-
tion of malignancy.82 EUS-FNB provides core tissue with
preserved architecture of desmoplastic stroma and gland-
dular tissues to establish histological diagnosis of PDAC
and to differentiate malignancy from AIP, chronic pancre-
atitis, pancreatic lymphoma or tuberculosis. In addition,
it may provide additional tissue for molecular profiling
(such as immunohistochemistry, DNA sequencing or
RNA-based marker studies) and when morphological
retention of tissue architecture is needed for establishing
diagnosis and management.

**Technical feasibility considerations**

EUS-FNB is a technique similar to EUS-FNA to acquire
tissue for histological evaluation. There are various types of
FNB needles including a Fork tip, a Franseen tip and a
side opening needle which are designed to obtain a core
sample from the target tissue. The Fork tip needle design
has an additional sharp tip while the Franseen needle
has three cutting edges. A recent randomised control
trial (RCT) and a meta-analysis on 21 studies showed
no significant difference in diagnostic yield of Franseen
tip needle 92.7%–94% as compared with Fork tip FNB
needle 98%.83 84 Only one RCT showed higher diagnost-
cy rate of complications and technical success between two
approaches. Several RCTs have shown the superiority of
FNB over FNA to diagnose pancreatic cancers while some
RCT showed no difference in diagnostic accuracy, sensi-
tivity and specificity between two techniques (table 2).89–94

---

**Table 2** RCT comparing EUS-FNA and EUS-FNB for diagnosis of pancreatic cancers

<table>
<thead>
<tr>
<th>Study</th>
<th>Year of study</th>
<th>Total no of patients</th>
<th>Accuracy/diagnostic yield, FNA versus FNB (%)</th>
<th>Sensitivity, FNA versus FNB (%)</th>
<th>Specificity, FNA versus FNB (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheng et al80</td>
<td>2018</td>
<td>408</td>
<td>80 vs 91.4*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Van Riet et al82</td>
<td>2019</td>
<td>608</td>
<td>87 vs 78*</td>
<td>90 vs 82*</td>
<td>96 vs 91</td>
</tr>
<tr>
<td>Wang et al83</td>
<td>2016</td>
<td>408</td>
<td>80 vs 93</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vanbiervliet et al84</td>
<td>2014</td>
<td>80</td>
<td>92.5 vs 90</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lee et al84</td>
<td>2014</td>
<td>118</td>
<td>94.8 vs 98.3</td>
<td>94.6 vs 98.2</td>
<td>100 vs 100</td>
</tr>
<tr>
<td>Strand et al85</td>
<td>2014</td>
<td>32</td>
<td>93.8 vs 28.1*</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Statistically significant data.

EUS, endoscopic ultrasound; FNA, fine-needle aspiration; FNB, fine-needle biopsy; NA, not applicable; RCT, randomised control trial.
EUS-GUIDED THERAPEUTIC INTERVENTIONS
Endoscopic ultrasound-guided biliary drainage

Indications
In current practice, the most commonly used method for biliary drainage (BD) in the setting of pancreatic malignancy is ERCP-guided drainage which typically shows an excellent success rate of over 90%. BD with ERCP is challenging in cases of benign or malignant stricture of oesophagus or duodenum, anatomic or pathological abnormality of ampulla (such as malignant infiltration of ampulla or periampullary diverticulum), and in case of altered anatomy of gastrointestinal tract after bariatric gastric bypass surgeries. Due to difficult access to the ampulla, percutaneous transhepatic BD (PTBD) or surgical decompression are alternative procedures of choice after failed ERCP. The associated morbidities (such as risk of bleeding, infections, cholangitis, pancreatitis, catheter dislocation and bile leak) are high with these procedures (up to 33%). The failure rate of ERCP BD is 3%–10% specifically due to ampullary infiltration of pancreatic cancers. Currently, there is increasing use of EUS-BD in these patients.

Technical feasibility considerations
EUS-BD can be performed with either intrahepatic or extrahepatic techniques depending on the patient’s anatomy and technical feasibility. The intrahepatic techniques are EUS-guided hepatocostal drainage with a transhepatic needle, such as the rendezvous technique (EUS-RV), where the tip of the EUS probe is positioned along the lesser curvature of the stomach to visualize the dilated left hepatic duct. Under EUS and fluoroscopic guidance, a 19–22 G transgastric needle is inserted into the lumen of the left hepatic duct. The needle track is dilated with a 6.5 Fr cystotome to create a hepatogastric fistula and a fully covered self-expanding metal stent or lumen apposing metal stent (LAMS) can be placed for biliary decompression. A transpapillary stent could be deployed with antegrade advancement of the wire or with an EUS-guided rendezvous (EUS-RV) technique. In EUS-RV, a dilated biliary duct is punctured with a 19G needle, the guidewire is advanced through needle into duodenal lumen in an antegrade fashion and finally, retrograde cannulation of common bile duct (CBD) is performed with ERCP duodenoscope using the EUS directed guidewire.

The extrahepatic techniques include EUS-guided choledochoduodenostomy where the dilated CBD can be visualized by positioning tip of EUS scope in the duodenal bulb or antrum. After inserting a 19 G transduodenal needle into CBD, needle track is created over 0.035-inch guidewire and transluminal or transpapillary stent is deployed. Metal stent are preferred over plastic stents due to better safety profile, less risk of stent-related complications.

Safety
EUS-BD is an emerging technique with both technical and functional success rate over 90%. The technical and clinical success rates of EUS-BD and ERCP-BD are comparable, however, the advantages of EUS-BD over ERCP-BD are fewer adverse outcomes with low risk of postprocedure pancreatitis, longer stent patency with decreased reintervention need and increased quality of life.

Meta-analysis on 42 studies showed complications associated with EUS-BD are bile leakage 4.03%, hemorrhage 3.02%, migration of stent 0.78% and postprocedure pain 15.1%. The utility of metal stents has significantly reduced stent-related complications of BD. When comparing intrahepatic with extrahepatic biliary decompression, there is no difference in success rate (90.4% vs 84.3%) and overall outcome (32.6% vs 35.6%) between two approaches.

Accuracy
The efficacy and technical success rate of EUS-BD is improving. The rate of complications can be reduced by performing this procedure in expert centres. The long learning curve of this technique is directly associated with low rates of complications and high success rate. A group of 40 international experts suggested that EUS-BD should be performed by an expert endoscopist who master the EUS and ERCP techniques and has at least 4–5 years of experience (approximately 200–300 EUS and ERCP annually) with success rate over 95% for standard ERCP. Currently, there are no significant data on the accuracy of EUS-BD due to limited use of this technique as ERCP-BD is still the first-line procedure of choice for biliary decompression whenever possible. Further RCTs are required to determine further safety and accuracy of EUS-BD. The selection of intrahepatic or extrahepatic techniques is based on the patient’s clinical presentation, anatomical location of pathologic lesions and preference of endoscopist.

Endoscopic ultrasound-fine needle injection
Indications
EUS-fine needle injection (FNI) is a rapidly emerging technique to deliver implants and injections into pancreatic lesions under direct EUS visualization. The preoperative EUS-guided injection of dyes to tattoo tumor is increasingly used for localization of operable pancreatic lesions. EUS-guided implantation of fiducial markers into the tumor enables targeted radiation therapy to the pancreatic tumors. Similarly, the direct injection of certain antitumor agents into the tumor may provide localized chemotherapy. The advantage of localised chemotherapy is to expose targeted lesion with high concentration of chemotherapeutic agents while minimizing the risk of systemic toxicities.


Technical feasibility considerations
A 19G or 22G fine needle is inserted into the targeted lesions under direct EUS visualization. EUS-guided fine needle tattooing (EUS-FNT) is usually performed by injecting 2–5 mL sterile dye (carbon particles, indocyanine or India ink) into normal pancreatic tissue 2 cm away from tumor margins. A number of EUS-FNI agents, including ethanol, antitumor adenovirus vector (ONYX-015, TNERade), antitumor therapy (dendritic cells), gemcitabine, paclitaxel, have been experimentally used in humans with similar techniques. Additionally, EUS-guided placement of fiducial markers directly into pancreatic tumors, may be useful in radiation treatment planning.

Safety and accuracy
EUS-FNI is a very safe and minimally invasive method for both therapeutic and diagnostic interventions in the management of pancreatic cancers. The advantage of preoperative EUS-FNT is accurate identification of small pancreatic tumors during surgical resection which results in limited resection of pancreatic tissue, shorter operative time and fewer surgical complications. The technical success rate of EUS-brachytherapy (placement of radioactive seeds directly into the pancreas) is 85%–100%. EUS-guided brachytherapy, have shown an improvement in pain symptoms but not overall survival.

EUS-guided celiac plexus neurolysis and celiac plexus block
The injection of nerve-blocking agents using the celiac plexus neurolysis (CPN) plays an important role in the management of palliative pain in unresectable pancreatic cancers.

Indications
Pain management in pancreatic cancers is sometimes challenging in cases of inadequate pain control with non-opioid analgesics. EUS-guided CPN is a well-accepted nonpharmacological treatment option for pain management to improve quality of life. In patients with unresectable pancreatic cancers, EUS-CPN is associated with better pain control and reduction in the consumption of opioids.

Technical feasibility considerations
The celiac plexus is located below the diaphragm adjacent to the anterolateral aspect of the celiac trunk. EUS identifies the location of the celiac plexus at the junction between the celiac trunk and aorta. There are two types of endoscopic approaches for performing CPN including ‘central’ and ‘bilateral’ techniques. A linear echoendoscope is positioned in the body of the stomach to identify abdominal aorta. The echoendoscope traces the aorta down to the celiac trunk. In the central approach, the needle is directed centrally at the junction of aorta and the celiac artery. In the bilateral approach, the echoendoscope is rotated clockwise to advance the needle adjacent to the celiac artery to the point of origin of SMA from aorta. A 10 mL of 0.25% bupivacaine is injected adjacent and anterior to the celiac artery depending on above-mentioned approaches. This is followed by the injection of neurolytic agents either 10 mL of dehydrated 98% alcohol or phenol. A dedicated 20 G needle with multiple side holes assists in the effective spread of injecting agents into the celiac plexus is available. The needle should be flushed with 3 mL of normal saline before withdrawal to prevent postprocedural abdominal pain secondary to the seeding of neurolytic agent in the needle track.

Safety and accuracy
EUS-guided CPN is a relatively safe alternative than CT or fluoroscopically guided plexus neurolysis in the management of pancreatic cancer pain. A meta-analysis on pain management in pancreatic cancer patients showed a long-term success rate of 72% with EUS-CPN and is a reasonable option for patients with tolerance to narcotic analgesics. Another meta-analyses including 17 studies have shown 80.12% pooled pain relief related to pancreatic cancers with EUS-CPN techniques. The pain-relieving effect of the bilateral technique is long-lasting and much higher 84.54% than central technique 45.99%. Overall EUS-CPN and EUS-ceeliac plexus block (CPB) are safe, and effective palliative methods in pancreatic cancers which allow the patients to cut-down their narcotics and improve their pain control. Moreover, the injection on both sides of the celiac artery had a higher pain-relieving success rate compared with injection on one side (85% vs 46%). The reported rate of complications is 2%–7% with EUS-CPB while up to 21% with EUS-CPN which is relatively lower than other modalities. The most common transient complications are local pain (36%), hypotension (33%) and diarrhea (23%).

Role of EUS in gastric outlet obstruction
Indications
Pancreatic cancers are associated with gastric outlet obstruction (GOO) in approximately 10%–20% patients. The progression of primary pancreatic tumor causes GOO due to extrinsic duodenal compression in most cases. Nausea, nonbilious vomiting, symptoms of malnutrition and dehydration are the initial symptoms of GOO. The quality of life in these patients is poor due to malnourishment and pancreatic cancer pain. The goal of palliative treatment is to relieve symptoms of GOO and improve nutritional status. Typically, palliative treatment of malignant GOO has been performed with established methods including open or laparoscopic surgical gastrojejunostomy (GJ) and duodenal stenting. Recently established minimal invasive endoscopic techniques including EUS-GJ are novel and promising modalities in the management of GOO.

Technical feasibility considerations
EUS-GJ is technically challenging than conventional duodenal stenting and should be performed by the expert therapeutic endoscopist. In the direct
EUS-gastroenterostomy (GE) approach, a therapeutic forward-viewing echoendoscope is used to fill small bowel with mixture of saline, contrast and methylene blue. A transgastric 19 G needle is used to puncture small bowel distal to GOO. The needle position is confirmed with the aspiration of blue-tinged fluid and enterogram. After withdrawing the needle, a cautery assisted LAMS is deployed across small bowel and gastric body. A balloon-assisted GE is another approach of EUS-GE in which a guide-wire is placed across the GOO, followed by inflation of the balloon with contrast fluid. The contrast filled balloon is then punctured with EUS-guided 19 G needle transgastrically. A guidewire is then advanced into small bowel followed by deployment of LAMS to create gastroenterostomy.

Safety and accuracy

EUS-GJ is a safe modality in the management of malignant GOO. These minimally invasive techniques offer the potential benefits of surgical bypass with higher technical success (90%–100%), clinical success rates (80%–95%) and low risk of adverse events or procedural complications. The reported complications of EUS-GJ are perforation, peritonitis, haemorrhage and luminal obstruction of the stent due to food impaction. EUS-GE should be avoided in patients with perigastric varices and those with massive ascites due to increased risk of bleeding, peritonitis and leakage or anastomotic dehiscence. A recent meta-analysis including 12 studies showed adverse events in 12% of patients while 9% of patients showed recurrent symptoms requiring reintervention.

Conclusion

EUS plays an important role in the evaluation of pancreatic masses and in determination of the accurate stage of pancreatic cancers by providing cytological and histological confirmation. Additionally, EUS-guided therapeutic interventions are promising modalities providing effective BD particularly in individuals where ERCP is not feasible. Further RCTs are needed to establish further validations of newer endoscopic techniques for the management of pancreatic malignancy.

Twitter Muhammad Nadeem Yousaf @M_Nadeem_Yousaf

Contributors MNY: Manuscript writing and overall data collection. FSC, AE, ALS, TM, PJ and HRA: Review of manuscript and data and proofreading. JF: Manuscript supervision.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. This is a review article and all data are available online.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Muhammad Nadeem Yousaf http://orcid.org/0000-0002-7979-8929

REFERENCES


